CDC recommends Pfizer and Moderna vaccines over Johnson & Johnson due to rare blood clotting issue

The CDC now recommends that Americans take the mRNA vaccines made by Pfizer and Moderna instead of the one-shot Johnson & Johnson vaccine due to rare but serious blood clots.

The agency’s Advisory Committee on Immunization Practices unanimously voted on Thursday to give a preferential recommendation to Moderna and Pfizer’s shots. 

“More than 200 million Americans have completed their primary vaccine series, providing protection against COVID-19, preventing millions of cases and hospitalizations, and saving over a million lives,” CDC Director Rochelle Walensky said in a statement. “Today’s updated recommendation emphasizes CDC’s commitment to provide real-time scientific information to the American public.”

The CDC temporarily halted Johnson & Johnson’s vaccine in April while scientists investigated the blood clots, which are known as “thrombosis with thrombocytopenia syndrome.”

Syringes filled with the Johnson & Johnson vaccine are shown, Thursday, May 13, 2021, at a mobile vaccination site at the Greater Bethel Church in Miami. ((AP Photo/Wilfredo Lee))

Regulators eventually decided that the benefits of the Johnson & Johnson vaccine outweighed the risks, but the FDA released new data this week showing that more cases have occurred in the summer and fall. 

Women between the ages of 30 and 49 are most affected by the blood clotting issue at a rate of about 1 in 100,000 shots. 

Health officials have confirmed 54 cases of the blood clots, nine of which have been fatal, CDC official Dr. Isaac See said Thursday. Two more deaths are suspected to be related to the blood clotting issue. 

SUPPLY CHAIN ISSUES IMPACTING PHARMACIES: WHAT TO KNOW

A CDC official told FOX Business that individuals who received the Johnson & Johnson vaccine should still receive a booster dose two months after their initial vaccine. 

If an individual received a Johnson & Johnson shot for their primary dose and then a booster of any vaccine, then they do not need to be re-vaccinated with an mRNA COVID-19 vaccine, according to the official. 

Michelle Falgout, a registered nurse, administers a dose of the Johnson & Johnson COVID-19 vaccine to Kerri Houston at a Florida Department of Health in a Pinellas County vaccination event held at the Salvador Dali Museum in St. Petersburg, Flori

Symptoms of blood clots – including severe headaches, abdominal pain, back pain, and nausea – usually occur 6 to 14 days after receiving the Johnson & Johnson vaccine, according to the American Society of Hematology

Only about 16 million doses of the Johnson & Johnson vaccine have been administered in the United States, compared to about 470 million doses of the vaccines made by Pfizer and Moderna. 

COVID-19 VACCINE EFFECTIVENESS WILL LIKELY DROP AGAINST OMICRON VARIANT, MODERNA CEO SAYS

The Johnson & Johnson vaccine is a viral vector vaccine, meaning that it replaces a small piece of the genetic instructions in a harmless adenovirus with genetic instructions for the SARS-CoV-2 spike protein. When the vaccine is injected, our cells recognize that the spike protein isn’t supposed to be there and produce antibodies to fight it. 

Liesl Eibschutz, a medical student from Dartmouth University, loads a syringe with Pfizer COVID-19 vaccine before giving it to people on the first day that people ages 16 and up can receive the vaccine at Kedren Health on Thursday, April 15, 2021 in

AstraZeneca’s COVID-19 vaccine, which was produced in the United Kingdom, is also a viral vector vaccine and has led to similar blood clotting issues. 

CLICK HERE TO READ MORE ON FOX BUSINESS

Several other countries have already recommended mRNA vaccines over the viral vector vaccines, or set age limits for the Johnson & Johnson and AstraZeneca vaccines. 

COVID-19 itself can also cause blood clots. The risk of developing cerebral venous thrombosis or portal vein thrombosis is “significantly increased after COVID-19,” according to a University of Oxford study in April. 

The Associated Press contributed to this report.  

Applied for Go Fashion shares in IPO? What GMP signals about the issue

Go Fashion IPO: After three days of bidding, Go Fashion IPO got subscribed 135.46 times. The public issue worth 1,013.61 crore got subscribed 49.70 times in the retail category, 100.73 in the QIB category, and 262.08 in the NII category. Meanwhile in grey market, Go Fashion share price has corrected for second successive day. As per the market observers, shares of go Fashion are available at a premium of 380 in grey market today.

Go Fashion IPO GMP

According to the market observers, Go Fashion IPO grey market premium (GMP) today is 380, which is 90 down from its yesterday’s grey market premium of 470. They said that such a fall in the current nosediving market is quite expected. They said that Go Fashion IPO grey market premium has remained around 500 since it became available for bidding. This dip in the grey market price of Go Fashion IPO is due to the fresh selloff on Monday. They said that one should feel relieved as the fall in Go Fashion grey market price is still not to the tune of stock market fall.

What this GMP mean?

Market observers went on to add that GMP reflects an expected listing gain from the public issue. As Go Fashion IPO GMP today is 380, it means that grey market is expecting that Go Fashion shares would list at around 1070 ( 690 + 380), which is around 55 per cent higher from its upper price band.

However, market observers maintained that one should not look at grey market premium as a concrete indicator about an IPO. In fact, it’s financials of the company that gives actual picture of the company.

Highlighting the fundamentals in regard to Go Fashion IPO; Nitin Shahi, Executive Director at Findoc said, “Go Fashion is one of the leading companies in women bottom-wear Industry. The company has a well-diversified product portfolio along with the multi-channel pan India distribution network. Moreover, company has a demonstrated track record of strong financial performance. Further, retail women bottom-wear market is a growing market. The share of organized retailing within women’s Apparels has increased from 19 per cent in 2015 to 27 per cent in the year 2020 is expected to reach 42 per cent by fiscal 2025.”

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint.

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint.
Download
our App Now!!

Have you downloaded AUTO TODAY September 2021 issue yet?

Vehicle These days September 2021 challenge capabilities opinions of the new Mahindra XUV700, Hyundai i20 N Line, 2021 MG Hector, Land Rover Defender 90, 2021 Honda Amaze, new Royal Enfield Common 350 to identify a number of along with Hyundai Alcazar vs Tata Safari comparison and a total ton much more.

Auto Today September 2021 issue free download

Scroll down and head to the website link to down load your duplicate of the September 2021 problem of Car Now.

HIGHLIGHTS

  • Vehicle evaluations – Mahindra XUV700, 2021 MG Hector CVT, 2021 Honda Amaze, Land Rover Defender 90 & Hyundai i20 N Line.
  • Motorcycle opinions – Triumph Velocity Triple RS, Triumph Avenue Triple RS, 2021 Royal Enfield Classic 350 & 2021 TVS Apache RR 310.
  • Road check/comparison – Hyundai Alcazar vs Tata Safari.

The September 2021 problem of Auto Nowadays magazine is out and in scenario you have not presently, head to the link down below to download a free of charge duplicate to read the hottest on new automobiles, bikes as effectively as unique capabilities.

http://www.autotodayindia.com/emag

Our protect tale this thirty day period is eagerly predicted Mahindra XUV700 which has established rather a buzz with its intense pricing for a car or truck bigger than in the same way priced SUVs armed with impressive petrol and diesel motors. Our critique tells you all you need to know about it. Speaking of a few-row SUVs, this month’s issue sees the Hyundai Alcazar acquire on the Tata Safari in our Highway Check whilst our major tale aspects Jeep’s approaching 67-seater. Reviews this month consist of the Land Rover Defender 90, the shorter-wheelbase variation of the all-new SUV, the Honda Amaze facelift, the i20’s sportier version – i20 N Line – and the 2021 MG Hector which is now available with a CVT.

Auto Today September 2021

Switching to two wheels from four, the greatest 1st Trip story this thirty day period is the new generation Royal Enfield Vintage 350 which has been fully reinvented but in very familiar apparel. We have also ridden the updated Triumph Velocity Triple RS, Triumph Road Triple and the Apache RR 310. A exclusive function this thirty day period on TVS as we ride an RTR 200 straight from the manufacturing unit to the racetrack to speak you as a result of the advancement course of action. As always, we have received updates on our lengthy term fleet that sees the introduction of the Honda H’ness even though we bid adieu to the Royal Enfield Meteor. Moreover, there is all the most current from the Indian and international automotive scene. Appreciate the September situation of Auto Today and until eventually up coming, journey and drive risk-free.

Click on here for IndiaToday.in’s entire protection of the coronavirus pandemic.